BME:PHMBiotechs
Pharma Mar (BME:PHM) Stock Faces Clinical Setback Despite Royalty Strength
Pharma Mar stock closed at €80.15 after the market absorbed its half year 2026 update, leaving investors weighing a flat near term share price against a very different earnings picture. The company delivered resilient recurring oncology revenues and stayed cash generative, yet quarterly profit slipped into a small loss of €0.972m even as trailing twelve month earnings from continuing operations reached €56.126m.
The real story now sits on the longer horizon. Royalty growth, the Zepzelca...